Based on the recent earnings conference call, it is clear that Thermo Fisher Scientific had a strong start to the year and is well positioned for future growth. The company's financial performance in Q1 was impressive, with 11% year-over-year revenue growth and a 16% increase in adjusted EPS. Additionally, the company expanded its adjusted operating margin by 90 basis points to 22.6%.

Thermo Fisher's growth strategy is based on developing high-impact, innovative new products, leveraging its scale in Asia-Pacific and emerging markets, and delivering its unique customer value proposition. The company made significant progress in each of these areas, launching new products across its technology portfolios, achieving strong growth in the Asia-Pacific region, and completing two strategic bolt-on acquisitions that strengthen its offering in bioproduction and digital science.

Furthermore, the recent acquisition of FEI is expected to contribute to the company's growth in the long term, with strong performance in both the life sciences and material science segments.

Based on these insights and financial metrics, it is recommended to adopt an 'overweight' investment stance on Thermo Fisher Scientific. The company's strong financial performance, strategic acquisitions, and position in key growth markets indicate a promising outlook for future growth and profitability.